Skip to Content

Precose (acarbose) Disease Interactions

There are 5 disease interactions with Precose (acarbose):

Major

Acarbose (Includes Precose) ↔ cirrhosis

Severe Potential Hazard, Moderate plausibility. Applies to: Cirrhosis

The use of acarbose is contraindicated in patients with primary cirrhosis.

Major

Acarbose (Includes Precose) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Acarbose may accumulate in patients with renal impairment. Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with acarbose should be administered cautiously in patients with renal dysfunction. The manufacturer does not recommend its use in patients with significantly impaired renal function.

References

  1. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  2. Balfour JA, McTavish D "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs 46 (1993): 1025-54
  3. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
Major

Alpha-glucosidase inhibitors (Includes Precose) ↔ diabetic ketoacidosis

Severe Potential Hazard, Moderate plausibility. Applies to: Diabetic Ketoacidosis

The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.

Major

Alpha-glucosidase inhibitors (Includes Precose) ↔ intestinal disease

Severe Potential Hazard, Moderate plausibility. Applies to: Colonic Ulceration, Intestinal Obstruction, Malabsorption Syndrome, Colitis/Enteritis (Noninfectious)

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

References

  1. Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
  2. "Product Information. Glyset (miglitol)." Bayer, West Haven, CT.
  3. Nishii Y, Aizawa T, Hashizume K "Ileus: a rare side effect of acarbose." Diabetes Care 19 (1996): 1033
  4. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
  5. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
View all 5 references
Moderate

Acarbose (Includes Precose) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice. Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day. Therapy with acarbose should be administered cautiously in patients with liver disease. Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter. If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.

References

  1. Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
  2. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  3. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
  4. Andrade RJ, Lucena MI, Rodriguezmendizabal M "Hepatic injury caused by acarbose." Ann Intern Med 124 (1996): 931
  5. Balfour JA, McTavish D "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs 46 (1993): 1025-54
View all 5 references

Precose (acarbose) drug interactions

There are 670 drug interactions with Precose (acarbose)

Precose (acarbose) alcohol/food interactions

There is 1 alcohol/food interaction with Precose (acarbose)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide